OFFICE LEASEOffice Lease • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Utah
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is dated as of September ___, 2018, between VESTAR GATEWAY, LLC, a Delaware limited liability company (“Landlord”), and RECURSION PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL....License Agreement • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and Option Agreement (this “Agreement”), dated as of August 28th, 2020 (the “Effective Date”), is made by and between Recursion Pharmaceuticals, Inc., a Delaware corporation with offices at 41 S Rio Grande Street, Salt Lake City, UT 84101 (“Recursion”) and Bayer AG, a German corporation, with offices at 42096 Wuppertal, Germany (“Bayer”). Each of Recursion and Bayer may be referred to herein as a “Party” or together as the “Parties”.
AMENDED AND RESTATED LEASE BY AND BETWEEN BERRUETA FAMILY L.P., LESSOR AND MOUSERA, INC., LESSEE Milpitas, California July 27, 2015Lease • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED LEASE, referred to herein as this “Lease,” is made and entered into as of July 27, 2015, by and between BERRUETA FAMILY L.P., a California limited partnership, hereafter referred to as “Lessor,” and MOUSERA, INC., a Delaware corporation, hereafter referred to as “Lessee” or “Mousera”.
LEASE AGREEMENT By and Between: INDUSTRY OFFICE SLC, LLC a Delaware limited liability company LANDLORD and RECURSION PHARMACEUTICALS, INC., a Delaware corporation TENANT 650 South 500 West Salt Lake City, UT 84101Office Lease • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Utah
THIS INDUSTRY COMMERCIAL BUILDING OFFICE LEASE (this “Lease”) is dated as of the Effective Date, by and between Landlord and Tenant. Landlord and Tenant for themselves and their successors and assigns, hereby agree as follows:
RECURSION PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 1, 2020Investors’ Rights Agreement • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of September 1, 2020, and is among Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the persons and entities listed on Exhibit A (the “Existing Investors”), the persons and entities listed on Exhibit B (the “New Investors,” and together with the Existing Investors, the “Investors”) and the persons and entities listed on Exhibit C (the “Founders”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL....License Agreement • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (“Agreement”) is dated as of May 1, 2020 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited having a business address at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) and Recursion Pharmaceuticals, Inc., having a business address at 41 S. Rio Grande Street, Salt Lake City, UT 84101, USA (“Recursion”). Each hereunder may be referred to separately as a “Party” or collectively as the “Parties”.
AMENDED AND RESTATED LICENSE AGREEMENT dated February 9th, 2016 between RECURSION PHARMACEUTICALS, LLC and UNIVERSITY OF UTAH RESEARCH FOUNDATIONLicense Agreement • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Utah
THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is entered into this 9th day of February, 2016 (“Restatement Date”) by and between the UNIVERSITY OF UTAH RESEARCH FOUNDATION, a Utah non-profit corporation, having its principal place of business at 615 Arapeen Drive, Suite 310, Salt Lake City, UT 84108, hereinafter referred to as “Licensor,” and Recursion Pharmaceuticals, LLC, a Delaware limited liability company, having its principal place of business at 383 Colorow Dr., Salt Lake City, UT 84108, hereinafter referred to as “Licensee.” Licensor and Licensee may be referred to herein solely as a “party” or jointly as the “parties” as the case may be.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS “[***]”. All provisions are subject to...Exclusive License Agreement • March 3rd, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Ohio
This Exclusive License Agreement (the “Agreement”) is made this 21st day of December, 2018 (the “Effective Date”) by and between the Ohio State Innovation Foundation, with an address at 1524 North High Street, Columbus, OH 43201 (hereinafter, “OSIF”) and Recursion Pharmaceuticals, Inc., with an address at 41 S. Rio Grande Street, Salt Lake City, UT 84101 (hereinafter, “Licensee”); collectively, “Parties”, or singly, “Party”.
